-
1
-
-
44649202740
-
Molecular mechanisms of inflammatory bone damage: Emerging targets for therapy
-
Herman S, Kronke G, Schett G,. Molecular mechanisms of inflammatory bone damage: emerging targets for therapy. Trends Mol Med 2008; 14: 245-53.
-
(2008)
Trends Mol Med
, vol.14
, pp. 245-253
-
-
Herman, S.1
Kronke, G.2
Schett, G.3
-
2
-
-
0033524159
-
Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomized phase III trial
-
et al. ATTRACT Study Group.
-
Maini R, St.Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al, for the ATTRACT Study Group. Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial. Lancet 1999; 354: 1932-9.
-
(1999)
Lancet
, vol.354
, pp. 1932-1939
-
-
Maini, R.1
Stclair, E.W.2
Breedveld, F.3
Furst, D.4
Kalden, J.5
Weisman, M.6
-
3
-
-
0034735842
-
Infliximab and methotrexate in the treatment of rheumatoid arthritis
-
et al. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.
-
Lipsky PE, van der Heijde DM, St.Clair EW, Furst DE, Breedveld FC, Kalden JR, et al, for the Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000; 343: 1594-602.
-
(2000)
N Engl J Med
, vol.343
, pp. 1594-1602
-
-
Lipsky, P.E.1
Van Der Heijde, D.M.2
Stclair, E.W.3
Furst, D.E.4
Breedveld, F.C.5
Kalden, J.R.6
-
4
-
-
11144354315
-
Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate
-
et al. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.
-
Maini RN, Breedveld FC, Kalden JR, Smolen JS, Furst D, Weisman MH, et al, for the Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 2004; 50: 1051-65.
-
(2004)
Arthritis Rheum
, vol.50
, pp. 1051-1065
-
-
Maini, R.N.1
Breedveld, F.C.2
Kalden, J.R.3
Smolen, J.S.4
Furst, D.5
Weisman, M.H.6
-
5
-
-
8444239359
-
Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized, controlled trial
-
et al. Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset Study Group.
-
St.Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, et al, for the Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset Study Group. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004; 50: 3432-43.
-
(2004)
Arthritis Rheum
, vol.50
, pp. 3432-3443
-
-
Stclair, E.W.1
Van Der Heijde, D.M.2
Smolen, J.S.3
Maini, R.N.4
Bathon, J.M.5
Emery, P.6
-
6
-
-
0037231533
-
Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial
-
et al.
-
Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003; 48: 35-45.
-
(2003)
Arthritis Rheum
, vol.48
, pp. 35-45
-
-
Weinblatt, M.E.1
Keystone, E.C.2
Furst, D.E.3
Moreland, L.W.4
Weisman, M.H.5
Birbara, C.A.6
-
7
-
-
0348109372
-
Adalimumab, a fully human anti-tumor necrosis factor-α monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: Results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis)
-
et al.
-
Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D, et al. Adalimumab, a fully human anti-tumor necrosis factor-α monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 2003; 30: 2563-71.
-
(2003)
J Rheumatol
, vol.30
, pp. 2563-2571
-
-
Furst, D.E.1
Schiff, M.H.2
Fleischmann, R.M.3
Strand, V.4
Birbara, C.A.5
Compagnone, D.6
-
8
-
-
0033574147
-
Etanercept therapy in rheumatoid arthritis: A randomized, controlled trial
-
et al.
-
Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, et al. Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial. Ann Intern Med 1999; 130: 478-86.
-
(1999)
Ann Intern Med
, vol.130
, pp. 478-486
-
-
Moreland, L.W.1
Schiff, M.H.2
Baumgartner, S.W.3
Tindall, E.A.4
Fleischmann, R.M.5
Bulpitt, K.J.6
-
9
-
-
0034735827
-
A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis
-
et al.
-
Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343: 1586-93.
-
(2000)
N Engl J Med
, vol.343
, pp. 1586-1593
-
-
Bathon, J.M.1
Martin, R.W.2
Fleischmann, R.M.3
Tesser, J.R.4
Schiff, M.H.5
Keystone, E.C.6
-
10
-
-
10744223002
-
Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: Double-blind randomised controlled trial
-
et al. TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) Study Investigators.
-
Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al, for the TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) Study Investigators. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004; 363: 675-81.
-
(2004)
Lancet
, vol.363
, pp. 675-681
-
-
Klareskog, L.1
Van Der Heijde, D.2
De Jager, J.P.3
Gough, A.4
Kalden, J.5
Malaise, M.6
-
11
-
-
0031660364
-
Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis
-
et al.
-
Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41: 1552-63.
-
(1998)
Arthritis Rheum
, vol.41
, pp. 1552-1563
-
-
Maini, R.N.1
Breedveld, F.C.2
Kalden, J.R.3
Smolen, J.S.4
Davis, D.5
Macfarlane, J.D.6
-
12
-
-
31044442965
-
The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment
-
et al. PREMIER Investigators.
-
Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, et al, for the PREMIER Investigators. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006; 54: 26-37.
-
(2006)
Arthritis Rheum
, vol.54
, pp. 26-37
-
-
Breedveld, F.C.1
Weisman, M.H.2
Kavanaugh, A.F.3
Cohen, S.B.4
Pavelka, K.5
Van Vollenhoven, R.6
-
13
-
-
68049099274
-
Golimumab, a human anti-tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis
-
et al.
-
Emery P, Fleischmann RM, Moreland LW, Hsia EC, Strusberg I, Durez P, et al. Golimumab, a human anti-tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum 2009; 60: 2272-83.
-
(2009)
Arthritis Rheum
, vol.60
, pp. 2272-2283
-
-
Emery, P.1
Fleischmann, R.M.2
Moreland, L.W.3
Hsia, E.C.4
Strusberg, I.5
Durez, P.6
-
14
-
-
79955554422
-
The effects of golimumab on radiographic progression in rheumatoid arthritis: Results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy
-
et al.
-
Emery P, Fleischmann R, van der Heijde D, Keystone EC, Genovese MC, Conaghan PG, et al. The effects of golimumab on radiographic progression in rheumatoid arthritis: results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy. Arthritis Rheum 2011; 63: 1200-10.
-
(2011)
Arthritis Rheum
, vol.63
, pp. 1200-1210
-
-
Emery, P.1
Fleischmann, R.2
Van Der Heijde, D.3
Keystone, E.C.4
Genovese, M.C.5
Conaghan, P.G.6
-
15
-
-
0023945481
-
The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis
-
et al.
-
Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
-
(1988)
Arthritis Rheum
, vol.31
, pp. 315-324
-
-
Arnett, F.C.1
Edworthy, S.M.2
Bloch, D.A.3
McShane, D.J.4
Fries, J.F.5
Cooper, N.S.6
-
16
-
-
0018882143
-
Measurement of patient outcome in arthritis
-
Fries JF, Spitz P, Kraines RG, Holman HR,. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 137-45.
-
(1980)
Arthritis Rheum
, vol.23
, pp. 137-145
-
-
Fries, J.F.1
Spitz, P.2
Kraines, R.G.3
Holman, H.R.4
-
17
-
-
0029044362
-
American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis
-
et al.
-
Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727-35.
-
(1995)
Arthritis Rheum
, vol.38
, pp. 727-735
-
-
Felson, D.T.1
Anderson, J.J.2
Boers, M.3
Bombardier, C.4
Furst, D.5
Goldsmith, C.6
-
18
-
-
0026543255
-
Biannual radiographic assessments of hands and feet in a three-year prospective followup of patients with early rheumatoid arthritis
-
et al.
-
Van der Heijde DM, van Leeuwen MA, van Riel PL, Koster AM, van 't Hof MA, van Rijswijk MH, et al. Biannual radiographic assessments of hands and feet in a three-year prospective followup of patients with early rheumatoid arthritis. Arthritis Rheum 1992; 35: 26-34.
-
(1992)
Arthritis Rheum
, vol.35
, pp. 26-34
-
-
Van Der Heijde, D.M.1
Van Leeuwen, M.A.2
Van Riel, P.L.3
Koster, A.M.4
Van 'T Hof, M.A.5
Van Rijswijk, M.H.6
-
19
-
-
0030068817
-
Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism criteria
-
Van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL,. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism criteria. Arthritis Rheum 1996; 39: 34-40.
-
(1996)
Arthritis Rheum
, vol.39
, pp. 34-40
-
-
Van Gestel, A.M.1
Prevoo, M.L.2
Van 'T Hof, M.A.3
Van Rijswijk, M.H.4
Van De Putte, L.B.5
Van Riel, P.L.6
-
20
-
-
67449116863
-
Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate
-
et al.
-
Wells G, Becker JC, Teng J, Dougados M, Schiff M, Smolen J, et al. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis 2009; 68: 954-60.
-
(2009)
Ann Rheum Dis
, vol.68
, pp. 954-960
-
-
Wells, G.1
Becker, J.C.2
Teng, J.3
Dougados, M.4
Schiff, M.5
Smolen, J.6
-
21
-
-
77954453801
-
Estimated cutoff points for the 28-joint Disease Activity Score based on C-reactive protein in a longitudinal register of early arthritis
-
et al.
-
Castrejon I, Ortiz AM, Toledano E, Castaneda S, Garcia-Vadillo A, Patino E, et al. Estimated cutoff points for the 28-joint Disease Activity Score based on C-reactive protein in a longitudinal register of early arthritis. J Rheumatol 2010; 37: 1439-43.
-
(2010)
J Rheumatol
, vol.37
, pp. 1439-1443
-
-
Castrejon, I.1
Ortiz, A.M.2
Toledano, E.3
Castaneda, S.4
Garcia-Vadillo, A.5
Patino, E.6
-
22
-
-
0344127554
-
A simplified disease activity index for rheumatoid arthritis for use in clinical practice
-
et al.
-
Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) 2003; 42: 244-57.
-
(2003)
Rheumatology (Oxford)
, vol.42
, pp. 244-257
-
-
Smolen, J.S.1
Breedveld, F.C.2
Schiff, M.H.3
Kalden, J.R.4
Emery, P.5
Eberl, G.6
-
23
-
-
23944478301
-
Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: Validation of a clinical activity score
-
et al.
-
Aletaha D, Nell VP, Stamm T, Uffmann M, Pflugbeil S, Machold K, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 2005; 7: R796-806.
-
(2005)
Arthritis Res Ther
, vol.7
-
-
Aletaha, D.1
Nell, V.P.2
Stamm, T.3
Uffmann, M.4
Pflugbeil, S.5
Machold, K.6
-
24
-
-
34547400142
-
The Simplified Disease Activity Index (SDAI) and Clinical Disease Activity Index (CDAI) to monitor patients in standard clinical care
-
Aletaha D, Smolen JS,. The Simplified Disease Activity Index (SDAI) and Clinical Disease Activity Index (CDAI) to monitor patients in standard clinical care. Best Pract Res Clin Rheumatol 2007; 21: 663-75.
-
(2007)
Best Pract Res Clin Rheumatol
, vol.21
, pp. 663-675
-
-
Aletaha, D.1
Smolen, J.S.2
-
25
-
-
42449157502
-
Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: A randomized, double-blind, placebo-controlled, dose-ranging study
-
et al.
-
Kay J, Matteson EL, Dasgupta B, Nash P, Durez P, Hall S, et al. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum 2008; 58: 964-75.
-
(2008)
Arthritis Rheum
, vol.58
, pp. 964-975
-
-
Kay, J.1
Matteson, E.L.2
Dasgupta, B.3
Nash, P.4
Durez, P.5
Hall, S.6
-
26
-
-
0023154612
-
Measuring change over time: Assessing the usefulness of evaluative instruments
-
Guyatt G, Walter S, Norman G,. Measuring change over time: assessing the usefulness of evaluative instruments. J Chronic Dis 1987; 40: 171-8.
-
(1987)
J Chronic Dis
, vol.40
, pp. 171-178
-
-
Guyatt, G.1
Walter, S.2
Norman, G.3
-
27
-
-
77956847217
-
Disease activity and severity in early inflammatory arthritis predict hand cortical bone loss
-
Pye SR, Adams JE, Ward KA, Bunn DK, Symmons DP, O'Neill TW,. Disease activity and severity in early inflammatory arthritis predict hand cortical bone loss. Rheumatology (Oxford) 2010; 49: 1943-8.
-
(2010)
Rheumatology (Oxford)
, vol.49
, pp. 1943-1948
-
-
Pye, S.R.1
Adams, J.E.2
Ward, K.A.3
Bunn, D.K.4
Symmons, D.P.5
O'Neill, T.W.6
-
28
-
-
33644895018
-
Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: Results from the ASPIRE trial
-
et al. Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset (ASPIRE) Study Group.
-
Smolen JS, van der Heijde DM, St.Clair EW, Emery P, Bathon JM, Keystone E, et al, for the Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset (ASPIRE) Study Group. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum 2006; 54: 702-10.
-
(2006)
Arthritis Rheum
, vol.54
, pp. 702-710
-
-
Smolen, J.S.1
Van Der Heijde, D.M.2
Stclair, E.W.3
Emery, P.4
Bathon, J.M.5
Keystone, E.6
-
29
-
-
33646365588
-
Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: Two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial
-
et al. TEMPO Study Investigators.
-
Van der Heijde D, Klareskog L, Rodriguez-Valverde V, Codreanu C, Bolosiu H, Melo-Gomes J, et al, for the TEMPO Study Investigators. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum 2006; 54: 1063-74.
-
(2006)
Arthritis Rheum
, vol.54
, pp. 1063-1074
-
-
Van Der Heijde, D.1
Klareskog, L.2
Rodriguez-Valverde, V.3
Codreanu, C.4
Bolosiu, H.5
Melo-Gomes, J.6
-
30
-
-
84873197989
-
Comprehensive tuberculosis screening program in patients with inflammatory arthritides treated with golimumab, a human anti-tumor necrosis factor antibody, in phase III clinical trials
-
et al.
-
Hsia EC, Cush JJ, Matteson EL, Beutler A, Doyle MK, Hsu B, et al. Comprehensive tuberculosis screening program in patients with inflammatory arthritides treated with golimumab, a human anti-tumor necrosis factor antibody, in phase III clinical trials. Arthritis Care Res (Hoboken) 2013; 65: 309-13.
-
(2013)
Arthritis Care Res (Hoboken)
, vol.65
, pp. 309-313
-
-
Hsia, E.C.1
Cush, J.J.2
Matteson, E.L.3
Beutler, A.4
Doyle, M.K.5
Hsu, B.6
-
31
-
-
84863217872
-
Interferon-γ release assay versus tuberculin skin test prior to treatment with golimumab, a human anti-tumor necrosis factor antibody, in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis
-
et al.
-
Hsia EC, Schluger N, Cush JJ, Chaisson RE, Matteson EL, Xu S, et al. Interferon-γ release assay versus tuberculin skin test prior to treatment with golimumab, a human anti-tumor necrosis factor antibody, in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis. Arthritis Rheum 2012; 64: 2068-77.
-
(2012)
Arthritis Rheum
, vol.64
, pp. 2068-2077
-
-
Hsia, E.C.1
Schluger, N.2
Cush, J.J.3
Chaisson, R.E.4
Matteson, E.L.5
Xu, S.6
|